

Innovative cell therapy candidates across broad indications

INDICATION [DRUG]	TARGET	TECHNOLOGY	DISCOVERY STAGE R&D	IND-ENABLING PRECLINICAL STUDIES	CLINICAL STU
Multiple Myeloma [ABECMA]	BCMA	CAR T cell	BMS Partnership		
Multiple Myeloma [ABECMA]	BCMA	CAR T cell	BMS Partnership; Earlier Line Studies		
AML-Pediatric [SC-DARIC33]	CD33	Drug-Regulated; CAR T cell (DARIC)	TSVT Owned; SCRI Collaboration		
B-NHL [bbT369]	Dual B cell targets	Dual-Targeted CAR T cell Signal Enhanced Gene Edited	TSVT Owned		
Ovarian Cancer	MUC16	CAR T cell Pharmacologic Enhancements	REGN Collaboration		IND EOY 2023
Solid Tumors	MAGE-A4	TCR T cell Potency Enhanced	REGN/JW Collaboration		IIT EOY 2023 (JW)
AML-Adult [SC-DARIC33 Next-Gen]	CD33 + Undisclosed	Drug-Regulated CAR T cell Dual-Targeted Potency Enhanced	TSVT Owned		
Solid Tumors	Multiple	CAR / TCR T cell Potency Enhanced	Multiple TSVT Owned; Plus Regeneron Collab.		
Multiple Myeloma	Multiple	Multi-Targeted CAR T cell Potency Enhanced	TSVT Owned		
Additional Indications	Undisclosed	Multiple	Multiple TSVT Owned; Plus Novo Nordisk Collab.		

15

*Investigational New Drug application – IND; Investigator Initiated Trial – IIT; Newly Diagnosed Multiple Myeloma – NDMM